Inventor · disambiguated record
Karl-Hermann Schlingensiepen
Also filed as: SCHLINGENSIEPEN KARL-HERMANN
14 granted patents·9 pending applications·197 citations·filing 1994–2012
92Inventor score
Files withSCHLINGENSIEPEN KARL-HERMANN9BIOGNOSTIK GES6BOSSERHOFF ANJA KATRIN3ANTISENSE PHARMA GMBH2BIOGNOSTIK GESELLSCAHFT FUER B1
Top patents by PatentIndex Score
23 records- 0189US8936910B2Method for selective oligonucleotide modificationMITSCH ANDREAS·Filed 2011·Granted Jan 20, 2015·69 cites·11 claims
- 0288US7667027B2Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)BIOGNOSTIK GES·Filed 2006·Granted Feb 23, 2010·15 cites·2 claims
- 0384US6455689B1Antisense-oligonucleotides for transforming growth factor-β (TGF-β)BIOGNOSTIK GES·Filed 1994·Granted Sep 24, 2002·49 cites·6 claims
- 0481US8629117B2Method for stimulating the immune systemSCHLINGENSIEPEN KARL-HERMANN·Filed 2007·Granted Jan 14, 2014·2 cites·6 claims
- 0581US8476246B2Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta systemSCHLINGENSIEPEN KARL-HERMANN·Filed 2010·Granted Jul 2, 2013·11 cites·8 claims
- 0675US8703729B2Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that geneSCHLINGENSIEPEN KARL-HERMANN·Filed 2009·Granted Apr 22, 2014·1 cites·4 claims
- 0774US8097597B2Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumorsSCHLINGENSIEPEN KARL-HERMANN·Filed 2006·Granted Jan 17, 2012·2 cites·9 claims
- 0866US8822425B2Dosage of oligonucleotides suitable for the treatment of tumorsSCHLINGENSIEPEN KARL-HERMANN·Filed 2009·Granted Sep 2, 2014·2 cites·8 claims
- 0966US7563778B2Antisense oligonucleotide preparation methodBIOGNOSTIK GES·Filed 2004·Granted Jul 21, 2009·2 cites·5 claims
- 1065US6365345B1Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a roleBIOGNOSTIK GESELLSCAHFT FUER B·Filed 1994·Granted Apr 2, 2002·30 cites·5 claims
- 1160US2010160208A1Pharmaceutical compositionANTISENSE PHARMA GMBH·Filed 2009·Application pending·0 cites
- 1258US6972171B1Antisense oligonucleotide preparation methodBIOGNOSTIK GES·Filed 1998·Granted Dec 6, 2005·14 cites·9 claims
- 1353US2007196269A1Pharmaceutical compositionSCHLINGENSIEPEN KARL-HERMANN·Filed 2004·Application pending·0 cites
- 1451US7910563B2Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIAANTISENSE PHARMA GMBH·Filed 2004·Granted Mar 22, 2011·0 cites·17 claims
- 1549US8148493B2Method for inhibiting “melanoma inhibitory activity” MIABOSSERHOFF ANJA-KATRIN·Filed 2008·Granted Apr 3, 2012·0 cites·10 claims
- 1649US2003186906A1Mixture comprising an inhibitor or suppresor of a gene and a molecule binding to an expression product of that geneFiled 2001·Application pending·0 cites
- 1748US2003040499A1Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)BIOGNOSTIK GES·Filed 2002·Application pending·0 cites
- 1840US2011136893A1Oligonucleotide-, protein and/or peptide-polymer conjugatesSCHLINGENSIEPEN KARL-HERMANN·Filed 2007·Application pending·0 cites
- 1937US2007155685A1Pharmaceutical compositionSCHLINGENSIEPEN KARL-HERMANN·Filed 2005·Application pending·0 cites
- 2036US2012208774A1Method for inhibiting "melanoma inhibitory activity" miaBOSSERHOFF ANJA-KATRIN·Filed 2012·Application pending·0 cites
- 2135US2006128607A1Method for inhibiting "melanoma inhibitory activity" miaBOSSERHOFF ANJA-KATRIN·Filed 2002·Application pending·0 cites
- 2232US2006252716A1Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"SCHLINGENSIEPEN KARL-HERMANN·Filed 2001·Application pending·0 cites
- 2328US7326783B2Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasmsBIOGNOSTIK GES·Filed 1994·Granted Feb 5, 2008·0 cites·2 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →